Evidence map›Paper›PMID 41742238›Full record

Observational studyHarm reduction journal2026

From dust till dawn: patterns, motives, and risks of using smokable synthetic cathinones.

Antonia Bendau, Paale Bournot, Felix Betzler, Christopher Clay, Jonas Desaga, Twyla Michnevich

Abstract readObservational Study
In one paragraph

Observational study in Harm reduction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Antonia BendauDepartment of Psychiatry and Neurosciences CCM, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. antonia.bendau@charite.de.ORCID 0000-0002-3789-6205
Paale BournotDepartment of Psychiatry and Neurosciences CCM, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Felix BetzlerDepartment of Psychiatry and Neurosciences CCM, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.ORCID 0000-0002-1389-4870
Christopher Claysidekicks.berlin / Schwulenberatung Berlin gGmbH, Berlin, Germany.
Jonas DesagaDepartment of Psychiatry and Neurosciences CCM, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Twyla MichnevichDepartment of Psychiatry and Neurosciences CCM, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.ORCID 0000-0001-8253-1996

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSynthetic cathinones that are primarily smoked-such as pyrovalerone-type compounds, including MDPV, MDPHP, α-PHP, and α-PHiP, often referred to as "Monkey Dust"-have raised growing concern in clinical and harm reduction contexts due to their association with severe adverse psychological and behavioral effects. To date, detailed empirical user-level data on patterns of use and related aspects are absent. To address this gap, the present study aims to integrate first-hand perspectives and key characteristics of individuals using smokable synthetic cathinones to examine patterns of use and experiences associated with these substances.

methodsAs part of a large cross-sectional online survey on synthetic cathinone use in general, this study investigated the use of smokable synthetic cathinones in Germany (March-May 2025). A sample of 107 participants who reported use within the past 12 months was analyzed in detail. Quantitative measures-combined with content analysis of open-text responses-captured sociodemographics, patterns, settings, and motives of use, mental and physical health, adverse effects, reduction efforts, and support needs.

resultsThe majority of individuals who used smokable synthetic cathinones matched typical chemsex profiles (male, homosexual, urban, highly educated), yet non-chemsex use populations were also identified. One quarter reported using at least once a week and had high rates of problematic or dependent use indicators. One third reported a current mental disorder and symptoms of depression and anxiety were common. Frequently reported adverse effects included psychotic symptoms, anxiety, and panic attacks-consistent with the clinical profiles (e.g., sympathomimetic characteristics) typical of smokable synthetic cathinones-and were particularly prevalent among those reporting frequent use. Around one third reported applying safer use strategies, and nearly half had initiated reduction or cessation efforts.

conclusionsThis study provides the first systematic user-centered insights into the use of smokable synthetic cathinones, revealing heterogeneous populations with varying use patterns and risks. The findings highlight the need for targeted prevention and support strategies that address both chemsex-related and other emerging use profiles and settings. CLINICAL

trial registrationThe study was prospectively preregistered with the German Clinical Trials Register (DRKS; drks.de/search/en/trial/DRKS00035946) in February 2025.

Indexed as

AlkaloidsDesigner DrugsHarm ReductionMotivationSubstance-Related DisordersAdultCross-Sectional StudiesFemaleGermanyHumansIllicit DrugsMaleMiddle AgedSynthetic CathinoneYoung AdultAlkaloidscathinoneDesigner DrugsIllicit DrugsSynthetic CathinoneFlakkaFlexMDPHPMDPVMonkey dustNew psychoactive substancesPyrovaleroneResearch chemicalsα-PHiPα-PHP

Identifiers

PMID41742238
PMCPMC12961792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.